Quotient Limited (NASDAQ:QTNT) insider D J. Paul E. Cowan sold 100,000 shares of the stock in a transaction on Monday, September 18th. The shares were sold at an average price of $4.41, for a total transaction of $441,000.00. Following the sale, the insider now directly owns 26,666 shares of the company’s stock, valued at approximately $117,597.06. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Quotient Limited (QTNT) traded down 1.58% during midday trading on Tuesday, hitting $4.35. 117,700 shares of the stock traded hands. Quotient Limited has a 52-week low of $3.22 and a 52-week high of $8.64. The firm’s 50-day moving average is $4.24 and its 200-day moving average is $6.19. The company’s market cap is $62.54 million.
Quotient Limited (NASDAQ:QTNT) last issued its earnings results on Monday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.55). The firm had revenue of $6.83 million during the quarter, compared to analyst estimates of $5.70 million. Quotient Limited had a negative net margin of 381.66% and a negative return on equity of 13,050.41%. Analysts predict that Quotient Limited will post ($2.01) EPS for the current year.
ILLEGAL ACTIVITY WARNING: This piece was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.chaffeybreeze.com/2017/09/19/quotient-limited-qtnt-insider-d-j-paul-e-cowan-sells-100000-shares.html.
Several equities research analysts have weighed in on the stock. Zacks Investment Research raised shares of Quotient Limited from a “sell” rating to a “hold” rating in a research report on Wednesday, August 9th. ValuEngine raised shares of Quotient Limited from a “strong sell” rating to a “sell” rating in a research report on Friday, June 30th. Finally, BTIG Research reissued a “buy” rating and set a $12.00 price target on shares of Quotient Limited in a research report on Thursday, August 31st.
Several institutional investors and hedge funds have recently modified their holdings of QTNT. Northern Trust Corp purchased a new stake in shares of Quotient Limited during the second quarter valued at $1,783,000. State Street Corp purchased a new stake in shares of Quotient Limited during the second quarter valued at $1,728,000. Scholtz & Company LLC purchased a new stake in shares of Quotient Limited during the second quarter valued at $939,000. FNY Partners Fund LP purchased a new stake in shares of Quotient Limited during the first quarter valued at $636,000. Finally, Ameriprise Financial Inc. boosted its stake in shares of Quotient Limited by 5.2% during the second quarter. Ameriprise Financial Inc. now owns 1,829,895 shares of the company’s stock valued at $13,468,000 after purchasing an additional 90,057 shares during the period. 57.68% of the stock is owned by hedge funds and other institutional investors.
Quotient Limited Company Profile
Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.
Receive News & Ratings for Quotient Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient Limited and related companies with MarketBeat.com's FREE daily email newsletter.